Dr Jean Pierre Bizzari
Dr Bizzari began working in the pharmaceutical industry in 1983 as Head of Oncology at the Institut de Recherches Internationales SERVIER (France). From 1993 to 2002 he served as Vice President, Clinical Development Oncology at Rhône-Poulenc Rorer (Aventis). From 2002 until 2008, Dr Bizzari was the Vice President of Clinical Oncology Development at Sanofi-Aventis where he oversaw the approval of a number of drugs including ELOXATIN®, TAXOTERE® and ELITEK®.
Between 2008 to 2015 he was the executive vice president in charge of clinical development and was in charge of Revlimid, Pomalist and Abraxane. Dr Bizzari is a member of the Scientific Advisory Board of France's National Cancer Institute and Netrix Pharma, and serves on the board of Halozyme Therapeutics, Inc., Celator Pharmaceuticals, Inc., and Transgene SA. Dr Bizzari received his medical degree from the University of Nice (France). He is a specialist in oncology, having trained at La Pitié-Salpêtrière hospital in Paris, followed by training at the Ontario Cancer Institute and McGill Cancer Center. He was appointed in June 2015 to the Board of EORTC located in Bruxelles and elected Chairman of the New Drug Advisory Committee. He was appointed to the Scientific Advisory Board in 2016.